Scientific Program

Educational Session XI. Updates on Liquid Biopsy
Crystal 2 + Crystal 3
Chair : Young Whan Kim (Seoul National Univ., Korea)
Richie Soong (Yong Loo Lin School of Medicine, Singapore)
Time Topic Speaker
11:00-11:30 The Value Proposition of Liquid Biopsies to Precision Medicine Richie Soong (Yong Loo Lin School of Medicine, Singapore)
11:30-12:00 Liquid Biopsy Successfully Detects Best Drugs for Treating Lung Cancer James Yang (National Taiwan University Hospital, Taiwan)
12:00-12:30 Extracellular Vesicles(EV)-derived DNA for Liquid Biopsy in Lung Cancer Kye Young Lee (Konkuk Univ., Korea)
Educational Session XII. New Staging
Crystal 3
Chair : Geon Kook Lee (National Cancer Center, Korea)
Shiu-Feng Huang (Institute of Molecular and Genomic Medicine, Taiwan)
Time Topic Speaker
11:00-11:30 The Clinical Correlation of the 8th AJCC Staging System in Lung Adenocarcinoma Focusing on Early Stage Patients: Taiwan Experience Shiu-Feng Huang
(Institute of Molecular and Genomic Medicine, Taiwan)
11:30-12:00 Lung Cancers with Multiple Pulmonary Sites of
Involvement in the Eighth Edition of the TNM Classification
Hyo Sup Shim (Yonsei Univ., Korea)
12:00-12:30 Clinical Significance of New WHO Classification of Lung Cancer Hironori Ninomiya
(The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Japan)
Educational Session XIII. Lung Cancer Screening
Emerald
Chair : Jin Mo Goo (Seoul National Univ., Korea)
Matthijs Oudkerk(NELSON, Netherlands)
Time Topic Speaker
11:00-11:30 Korean Lung Cancer Screening Project: Initial Results Hyae Young Kim (National Cancer Center, Korea)
11:30-12:00 Lung Cancer Screening: European Experience Matthijs Oudkerk(NELSON, Netherlands)
12:00-12:30 Question and Answer
Industry-Sponsored Symposium V. [Boehringer Ingelheim]
Crystal 1
Chair : Taewon Jang (Kosin Univ., Korea)
Time Topic Speaker
07:50-08:30 Optimal Treatment Sequence in EGFR Targeted Therapy with Long Term Perspective Maximilian J. Hochmair
(Otto Wagner Hospital, Vienna, Austria)
Industry-Sponsored Symposium VI. [Novartis]
Crystal 2
Chair : Jin Seok Ahn (Sungkyunkwan Univ., Korea)
Time Topic Speaker
07:50-08:30 New Target Agent: Dabrafenib Plus Trametinib in Patients with BRAF Mutant Metastatic Non-Small Cell Lung Cancer James Chung-man Ho
(The University of Hong Kong, Hong Kong)
Industry-Sponsored Symposium VII. [Roche]
Crystal 3
Chair : Jeong Seon Ryu (Inha Univ., Korea)
Time Topic Speaker
07:50-08:30 The evolving power of immunotherapy : Tecentriq in Advanced Lung cancer Takashi Seto
(National Kyushu Cancer Center)
Plenary Session II. Predictive Marker for Immunotherapy Basic Perspective for Immunotherapy in Lung Cancer
Crystal 1 + Crystal 2 + Crystal 3
Chair : Myung Ju Ahn (Sungkyunkwan Univ., Korea)
Michael Boyer(Chris O'Brien Lifehouse, Australia)
Time Topic Speaker
09:00-09:30 Basic Perspective for Immunotherapy in Lung Cancer Eui Cheol Shin (KAIST, Korea)
09:30-10:00 Clinical Perspective for Current Immunotherapy in NSCLC Michael Boyer (Chris O'Brien Lifehouse, Australia)
10:00-10:30 Beyond PD-l/PD-L1 Inhibitor:
New Targeted Immunotherapy or Combination Therapy
Tien Hoang (Genentech, USA)